Energenesis Biomedical Co., Ltd, a clinical-stage biotech company developing therapies aimed at restoring cellular energy, has announced that it will showcase clinical application data for its investigational treatment ENERGI-F703DFU at the European Wound Management Association 2026 Annual Conference, taking place in Bremen from May 5–7, 2026.

As part of EWMA 2026, the company will deliver a presentation titled “ENERGI-F703DFU Gel: A Novel Topical Drug for the Treatment of Diabetic Foot Ulcers — Clinical Case Sharing.” The session is set for Wednesday, May 6, 2026, between 14:35 and 14:50 CEST during the New Tech Industry Symposium at the EWMA Arena. During the presentation, Energenesis will highlight real-world clinical case experiences illustrating how ENERGI-F703DFU may help accelerate wound closure and enhance recovery in patients suffering from chronic diabetic foot ulcers that are resistant to healing.

Lakewood-Amedex Biotherapeutics Inc, a clinical-stage biotech firm focused on developing a new category of powerful, rapid-acting, broad-spectrum antimicrobials known as the Bisphosphocin® class, has announced the addition of Joseph Tucker, Ph.D., to its Board of Directors. Dr. Tucker, who currently serves as Chief Executive Officer of Enveric Biosciences (Nasdaq: ENVB), joins the board following the company’s recent direct listing on Nasdaq. His appointment marks an important move to enhance governance and strategic direction as the company pursues its expansion plans.

With over 20 years of experience in the biotechnology sector, Dr. Tucker brings extensive leadership expertise across both public and private organizations, covering the full spectrum from early discovery to advanced-stage drug development. He leads Enveric Biosciences, a company dedicated to developing innovative neuroplastogenic small-molecule therapies aimed at treating neuropsychiatric and neurological conditions.

Kelvin Cooper, Ph.D., CEO of Lakewood-Amedex Biotherapeutics, noted that Dr. Tucker offers a strong blend of public company leadership, capital markets knowledge, and drug development expertise. He emphasized that Dr. Tucker’s experience in building and scaling biotech companies, along with his familiarity with public market dynamics, makes him a valuable addition to the board at a crucial stage. Following the Nasdaq listing, the company is prioritizing accelerated growth, and Dr. Tucker’s perspective is expected to support the advancement of its lead candidate, Nu-3, and broader pipeline development.

At Enveric, Dr. Tucker has overseen several strategic financing efforts and pipeline expansion initiatives, including progress toward a first-in-human clinical trial for its lead program, EB-003. Before joining Enveric, he held senior leadership roles—including CEO, Executive Chairman, and Director—at multiple biotechnology firms such as Willow Biosciences and Stem Cell Therapeutics. In these roles, he guided organizations through public offerings, mergers and acquisitions, and the development of clinical programs across diverse therapeutic areas. Throughout his career, he has raised over $100 million in funding, secured substantial non-dilutive capital, and completed numerous partnerships and licensing agreements.

Commenting on his new role, Dr. Tucker expressed enthusiasm about joining Lakewood-Amedex Biotherapeutics during a transformative period. He highlighted that the company’s Nasdaq listing creates a strong foundation for future growth and noted the promising potential of Nu-3 in tackling the global issue of antibiotic resistance. He also underscored the importance of developing new treatments for infected diabetic foot ulcers, an area with significant unmet medical need, and stated his eagerness to collaborate with the team to unlock the platform’s full potential.